Reports preliminary FY24 revenue $2.76B, consensus $2.74B. Plans to launch three new cancer tests in 2025, namely Cologuard Plus, next-generation colorectal cancer screening test, Oncodetect, molecular residual disease test, and Cancerguard, multi-cancer screening test.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences price target raised to $70 from $60 at Evercore ISI
- Exact Sciences price target lowered to $72 from $75 at BofA
- Exact Sciences price target raised to $75 from $65 at BTIG
- Exact Sciences price target raised to $86 from $82 at TD Cowen
- Closing Bell Movers: Semtech rises, Zoom falls after earnings